1Schroder F , Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate - specific antigen alone: a systematic. Eur Urol,2008,54(2) :274 -290.
3Thompson 1M, Ankerst DP. The benefits of risk assessment tools for prostate cancer. Eur Urol ,2012 ,61 (4) :662 - 663.
4Shariat SF. Inventory of prostate cancer predictive tools. CUIT Opin Urol, 2008, 18( 3) :279 - 296.
5Iasonos A. How to build and interpret a nomogram for cancer prog?nosis.J Clin Oncol ,2008,26 (8) : 1364 - 7130.
6Vickers AJ. Prostate - specific antigen velocity for early detection of prostate cancer: result from a large, representative, population -based cohort. Eur Urol,2009,56(5) :753 -760.
7Lee H.J. Image - based clinical decision support for transrectal ul?trasound in the diagnosis of prostate cancer: comparison of multiple logistic regression, artificial neural network, and support vector machine. Eur Radiol,2010,20( 6) :1476 -1484.
8Stephan C. A[- 2] proPSA - based artificial neural network sig?nificantly improves differentiation between prostate cancer and be?nign prostatic diseases. Prostate, 2009. 69 (2) : p. 198 - 207.
9HansenJ. Initial Prostate Biopsy: Development and Internal Vali?dation of a Biopsy - specific Nomogram Based on the Prostate Cancer Antigen 3 Assay. Eur Urol, 2012.
10Kader AK. Potential Impact of Adding Genetic Markers to Clinical Parameters in Predicting Prostate Biopsy Outcomes in Men Fol?lowing an Initial Negative Biopsy: Findings from the REDUCE Trial. Eur Urol,2012.
